Jane Street’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.6M | Sell |
80,600
-2,500
| -3% | -$332K | ﹤0.01% | 2462 |
|
|
2025
Q4 | $11.8M | Buy |
83,100
+69,700
| +520% | +$10.1M | ﹤0.01% | 2128 |
|
|
2025
Q3 | $1.88M | Sell |
13,400
-15,400
| -53% | -$2.09M | ﹤0.01% | 5055 |
|
|
2025
Q2 | $3.62M | Sell |
28,800
-418,000
| -94% | -$47.9M | ﹤0.01% | 3463 |
|
|
2025
Q1 | $49.4M | Buy |
446,800
+372,700
| +503% | +$47.2M | 0.01% | 669 |
|
|
2024
Q4 | $10.1M | Sell |
74,100
-60,600
| -45% | -$7.5M | ﹤0.01% | 1877 |
|
|
2024
Q3 | $15.5M | Buy |
134,700
+62,900
| +88% | +$8.62M | ﹤0.01% | 1465 |
|
|
2024
Q2 | $9.88M | Buy |
71,800
+31,000
| +76% | +$4.25M | ﹤0.01% | 2062 |
|
|
2024
Q1 | $5.63M | Buy |
40,800
+16,000
| +65% | +$2.19M | ﹤0.01% | 2457 |
|
|
2023
Q4 | $3.27M | Sell |
24,800
-48,700
| -66% | -$5.61M | ﹤0.01% | 3504 |
|
|
2023
Q3 | $8.27M | Sell |
73,500
-54,800
| -43% | -$5.77M | ﹤0.01% | 1991 |
|
|
2023
Q2 | $12.1M | Buy |
128,300
+119,800
| +1,409% | +$11.7M | ﹤0.01% | 1711 |
|
|
2023
Q1 | $860K | Sell |
8,500
-59,900
| -88% | -$6.23M | ﹤0.01% | 5302 |
|
|
2022
Q4 | $8.17M | Sell |
68,400
-36,300
| -35% | -$4.25M | ﹤0.01% | 1847 |
|
|
2022
Q3 | $11.1M | Sell |
104,700
-482,000
| -82% | -$48.9M | ﹤0.01% | 1588 |
|
|
2022
Q2 | $57.2M | Buy |
586,700
+476,500
| +432% | +$44M | 0.02% | 498 |
|
|
2022
Q1 | $10.3M | Sell |
110,200
-32,400
| -23% | -$2.75M | ﹤0.01% | 1951 |
|
|
2021
Q4 | $12.1M | Buy |
142,600
+63,000
| +79% | +$5.8M | ﹤0.01% | 1664 |
|
|
2021
Q3 | $7.63M | Buy |
79,600
+1,200
| +2% | +$113K | ﹤0.01% | 2158 |
|
|
2021
Q2 | $7.63M | Buy |
78,400
+3,600
| +5% | +$345K | ﹤0.01% | 2040 |
|
|
2021
Q1 | $7.27M | Buy |
74,800
+37,100
| +98% | +$3.89M | ﹤0.01% | 1908 |
|
|
2020
Q4 | $3.61M | Sell |
37,700
-19,700
| -34% | -$1.9M | ﹤0.01% | 2546 |
|
|
2020
Q3 | $5.52M | Buy |
57,400
+14,100
| +33% | +$1.63M | ﹤0.01% | 1743 |
|
|
2020
Q2 | $5.28M | Buy |
43,300
+19,200
| +80% | +$2.12M | ﹤0.01% | 1781 |
|
|
2020
Q1 | $2.09M | Buy |
24,100
+7,000
| +41% | +$685K | ﹤0.01% | 1980 |
|
|
2019
Q4 | $1.84M | Buy |
17,100
+14,000
| +452% | +$1.47M | ﹤0.01% | 2041 |
|
|
2019
Q3 | $279K | Sell |
3,100
-6,100
| -66% | -$570K | ﹤0.01% | 4256 |
|
|
2019
Q2 | $777K | Buy |
9,200
+3,700
| +67% | +$304K | ﹤0.01% | 3031 |
|
|
2019
Q1 | $485K | Buy |
+5,500
| New | +$460K | ﹤0.01% | 3713 |
|
|
2018
Q4 | – | Sell |
-2,300
| Closed | -$283K | – | 5442 |
|
|
2018
Q3 | $283K | Buy |
2,300
+100
| +5% | +$11.3K | ﹤0.01% | 4285 |
|
|
2018
Q2 | $216K | Buy |
+2,200
| New | +$197K | ﹤0.01% | 4482 |
|
|
2017
Q2 | – | Sell |
-6,200
| Closed | -$268K | – | 4686 |
|
|
2017
Q1 | $268K | Sell |
6,200
-30,100
| -83% | -$1.29M | ﹤0.01% | 3570 |
|
|
2016
Q4 | $1.41M | Sell |
36,300
-5,900
| -14% | -$267K | 0.01% | 1659 |
|
|
2016
Q3 | $2.14M | Buy |
42,200
+300
| +0.7% | +$14.9K | 0.01% | 1153 |
|
|
2016
Q2 | $1.9M | Buy |
+41,900
| New | +$1.93M | 0.01% | 1323 |
|
|
2015
Q4 | – | Sell |
-8,200
| Closed | -$326K | – | 4301 |
|
|
2015
Q3 | $326K | Buy |
+8,200
| New | +$396K | ﹤0.01% | 2709 |
|
Other funds holding NBIX
VPM
VCM
Jane Street's NBIX Position: Q1 2026 in Review
Jane Street increased its Neurocrine Biosciences (NBIX) stake by 19% in Q1 2026, buying an estimated $134K and bringing the position to 6,207 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #6933.
Jane Street first reported a position in NBIX in Q2 2013 and has held it in 44 quarters since. The position peaked at $34.8M in Q1 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Jane Street held 6,207 shares of Neurocrine Biosciences worth $818K as of Q1 2026.
- Jane Street bought 1,010 Neurocrine Biosciences shares in Q1 2026, an estimated $134K.
- Neurocrine Biosciences made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6933 holding.
- Jane Street first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 44 quarters since.
- Jane Street's Neurocrine Biosciences position peaked at $34.8M in Q1 2024.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.